Aberrant DNA hypermethylation of tumor suppressor genes is thought to be an early event in tumorigenesis. Many studies have reported the methylation status of individual genes with known involvement in cancer, but an unbiased assessment of the biological function of the collective of hypermethylated genes has not been conducted so far. Based on the observation that a variety of human cancers recapitulate developmental gene expression patterns (that is activate genes normally expressed in early development and suppress late developmental genes), we hypothesized that the silencing of differentiation-associated genes in cancer could be attributed in part to DNA hypermethylation. To this end, we investigated the developmental expression patterns of genes with hypermethylated CpG islands in primary human lung carcinomas and lung cancer cell lines. We found that DNA hypermethylation primarily affects genes that are expressed in late stages of murine lung development. Gene ontology characterization of these genes shows that they are almost exclusively involved in morphogenetic differentiation processes. Our results indicate that DNA hypermethylation in cancer functions as a selective silencing mechanism of genes that are required for the maintenance of a differentiated state. The process of cellular de-differentiation that is evident on both the microscopic and transcriptional level in cancer might at least partly be mediated by these epigenetic events. Our observations provide a mechanistic explanation for induction of differentiation upon treatment with DNA methyltransferase inhibitors.
Aberrant DNA hypermethylation of tumor suppressor genes is thought to be an early event in tumorigenesis. Many studies have reported the methylation status of individual genes with known involvement in cancer, but an unbiased assessment of the biological function of the collective of hypermethylated genes has not been conducted so far. Based on the observation that a variety of human cancers recapitulate developmental gene expression patterns (that is activate genes normally expressed in early development and suppress late developmental genes), we hypothesized that the silencing of differentiation-associated genes in cancer could be attributed in part to DNA hypermethylation. To this end, we investigated the developmental expression patterns of genes with hypermethylated CpG islands in primary human lung carcinomas and lung cancer cell lines. We found that DNA hypermethylation primarily affects genes that are expressed in late stages of murine lung development. Gene ontology characterization of these genes shows that they are almost exclusively involved in morphogenetic differentiation processes. Our results indicate that DNA hypermethylation in cancer functions as a selective silencing mechanism of genes that are required for the maintenance of a differentiated state. The process of cellular de-differentiation that is evident on both the microscopic and transcriptional level in cancer might at least partly be mediated by these epigenetic events. Our observations provide a mechanistic explanation for inducIntroduction Epigenetic modification of the genome through DNA methylation is central to maintaining differentiation and is often involved in tumorigenesis (Esteller, 2005; Armstrong et al., 2006) . The proximal promoter regions of 50-60% of human genes contain CpG-rich regions, known as CpG islands, which are normally 'protected' from methylation (Wang and Leung, 2004) . CpG island methylation is associated with transcriptional silencing of the gene through chromatin condensation and inhibition of transcription initiation (Keshet et al., 1986; Antequera et al., 1990; Baylin et al., 1998; Delgado et al., 1998) . The genome of cancer cells is often globally hypomethylated, mostly in scattered CpG dinucleotides in repetitive DNA sequences, which is believed to cause general genomic instability (Feinberg and Vogelstein, 1983; Fraga et al., 2005) . At the same time, certain CpG islands become hypermethylated in tumors, including those in the promoter regions of known tumor suppressor genes (Greger et al., 1989; Sakai et al., 1991; Gonzalez-Zulueta et al., 1995; Herman et al., 1995; Merlo et al., 1995; Hayslip and Montero, 2006) . Methylation-based silencing of tumor suppressors is thought to be an important mechanism for gene inactivation and an early event in tumorigenesis (Belinsky et al., 1998; Nuovo et al., 1999; Baylin and Herman, 2000; Nephew, 2003) . Consequently, genepromoter hypermethylation has become central to developing strategies for molecular screening, treatment and prognosis in a variety of cancers types (Tsou et al., 2002; Laird, 2003; Belinsky, 2004; Safar et al., 2005; Ushijima, 2005) .
Aberrant promoter hypermethylation is common to most cancers and in many cases exhibits tumor-type specificity (Costello et al., 2000; Esteller et al., 2001) . In lung cancer, the hypermethylation of CpG islands in promoter regions appears to be a common occurrence, as demonstrated by the analysis of genes from primary tumors, cell lines, patient sputum and serum (Rauch et al., 2008; Pfeifer and Rauch, 2009) . Methylation 'signatures' with promising diagnostic and prognostic ability have emerged as potential biomarkers for lung cancer progression (Tsou et al., 2002; Belinsky, 2004; Safar et al., 2005) . Safar et al. (2005) identified the methylation of three genes as determinant of prognostic groups with varying 1-and 2-year survival rates (Safar et al., 2005) . Marchevsky et al. (2004) discovered differing methylation levels at 20 loci that discriminate between small and non-small cell lung cancer (NSCLC) (Marchevsky et al., 2004) . Some of these differentially methylated genes are known or putative tumor suppressors, but a systematic characterization of the collective of hypermethylated genes may elucidate the biological significance of global hypermethylation patterns in lung cancer.
The lung cancer transcriptome is thought to contain a 'developmental signature', a set of genes that are collectively activated during development (Kho et al., 2004) . Genes that are normally only expressed in early developmental stages are re-expressed in lung cancer, while genes that are expressed in fully differentiated lung are repressed (Borczuk et al., 2003; Liu et al., 2006; Naxerova et al., 2008) . The mechanism by which these expression patterns arise is not fully understood. In 2007, (Rauch et al., 2007) identified a group of hypermethylated homeobox genes (HOX) in lung cancer that serve as key switches in development and differentiation, and thus may be targets during tumorigenesis. Meissner et al. (2008) recently showed that CpG islands associated with a specific set of developmentally regulated genes become hypermethylated on in vitro differentiation of embryonic stem cells (ESCs). To our knowledge, an unbiased genome-wide analysis of the developmental role of genes that are hypermethylated in primary lung tumors has not been performed and could provide a potential explanation for the re-activation of developmental expression patterns in cancer.
This study investigates the DNA methylation landscape of lung cancer in relation to normal lung development. We use CpG-island tiling array data from five primary NSCLC samples and matched normal lung to identify genes containing hypermethylated CpGislands in the human tumors. We then investigate the role of these genes in normal lung development. Our results show that genes that are hypermethylated in lung cancer tend to be expressed in late stages of lung development. This indicates that DNA methylation predominantly targets genes that are expressed in fully differentiated lung epithelium, presumably contributing to a reversal to 'embryonic' gene expression patterns in lung cancer. We confirm these results using expression data from lung cancer cell lines treated with demethylating agent 5-aza-2 0 -deoxycytidine. A Gene ontology (GO) analysis reveals that the hypermethylated genes are involved in differentiation-associated processes. Our results may explain the differentiation induced in cells treated with DNA methyltransferase inhibitors.
Results and discussion
Differentiation-associated genes are hypermethylated in human NSCLC We set out to investigate the hypothesis that aberrant promoter hypermethylation in lung cancer predominantly targets differentiation-associated genes. To identify genes that are specifically expressed in late stages of lung organogenesis, we analyzed a gene expression time course of murine lung development (GSE11539: whole lung expression profiles from C57BL/6J mice at E11.5, E13.5, E14.5, E16.5 and P5) and ordered all measured genes by their timing of expression (Naxerova et al., 2008) . The result is a list, subsequently referred to as a developmental timeline (DT), which contains at its top (left in a horizontal visualization, see Figure 1 ) genes that are active in early lung development and at its bottom (right) genes that are upregulated as the lung reaches full maturation. The DT provides a straightforward way to visualize the developmental expression patterns of a group of genes. In this study, we were interested in examining the developmental timing of (2008), we used principal components analysis to construct a DT for each developmental time series. Time series for lung, testis and ovary was profiled on the Affymetrix Mouse Genome 430 2.0 Array platform and ESC was profiled on Affymetrix Mouse Expression 430A and 430B Array platforms (Affymetrix, Santa Clara, CA, USA). Raw murine developmental data were normalized, and expression measures were calculated using the robust multi-array average within the Bioconductor R package (Irizarry et al., 2003; Gentleman et al., 2004) . Robust multi-array average-normalized intensity distributions for all samples are included in Supplementary Figure 1 . We reduced the DTs to include only those genes present on all platforms in the analysis (11 695 genes). The first principal component, PC1, is used as the DT, capturing 25-58% of the variation in the data. The bottom panel of this figure shows a heatmap of time series expression data for lung development. As shown, genes on the left of the DT are transcriptionally active early in development and genes on the right become more active toward the end of development. The DT is therefore a one-dimensional ordering of genes according to their expression pattern shown in the corresponding heatmap (arrow scale represents the number of genes on the DT). Heatmaps for all remaining time series are given in Supplementary Figure 2 .
Differentiation genes methylated in lung cancer E Helman et al genes that are hypermethylated in lung cancer. We obtained previously published CpG island methylation data for five human NSCLCs (GSE9622) (Rauch et al., 2008) . In this study, a methylated-CpG island recovery assay was combined with CpG island-tiling arrays to characterize genome-wide methylation levels at high resolution. Regions of adjacent probes with significantly raised levels of methylation compared with matched normal tissue were considered hypermethylated. A table of genes hypermethylated in each individual sample as well as genes consistently hypermethylated in at least four out of five samples is provided in Supplementary  Table 1a .
We next identified the location of the mouse homologs of the 102 genes that were consistently hypermethylated (in at least four of the five tumors) on our DT derived from murine lung development. If the hypermethylated genes shared no common developmental expression pattern, we would expect them to distribute randomly along the DT. If on the other hand they were enriched in genes that have a role in a particular developmental stage (early or late), we would expect them to accumulate on the left or right end, respectively. Figure 2a shows that genes that are hypermethylated in human NSCLCs indeed cluster in the 'late' fraction of the DT with high significance, indicating that they are enriched in genes that are upregulated upon differentiation of the lung. Presumably at least a portion of these genes can be expected to be causally implicated in establishment and maintenance of the differentiated state. Hypermethylation and subsequent silencing of these genes in NSCLC might therefore lead to the dedifferentiation that can be observed on the microscopic and molecular level.
We then wanted to test whether the coincidence of NSCLC hypermethylation and late developmental function was a tissue-specific phenomenon and restricted to lung development only. We selected three more developmental time courses for DT construction. The first one is a characterization of ESC differentiation (GSE3231: mESC lines R1, J1 and V6.5 undergoing undirected differentiation into embryoid bodies over a period of 2 weeks, with time points at 0, 6, 12, 18, 24, 36 and 48 h, and 4, 7, 9 and 14 days). We reasoned that if the hypermethylated NSCLC genes were general differentiation genes (with little or no specificity to lung development), we would see a similar distribution with a peak on the late end of the DT for ESC differentiation. Figure 2b shows that indeed NSCLC genes are mainly expressed late in ESC differentiation, but the trend is not as distinct as in lung development and does not quite reach significance. This indicates that while some genes that are hypermethylated in lung cancer have a role in general differentiation processes, there seems to be a high degree of specificity for lung development. We also selected two gene expression time courses of murine gonad development, because it is well-established that germ cells go through unique DNA methylation changes during their development (McLaren, 2000) . Multiple waves of demethylation leave the germ cell genome heavily hypomethylated (including the effacement of imprints and reactivation of the inactive X chromosome in females) shortly after primordial germ cells have settled in the genital ridge at E11.5 (Hajkova et al., 2002; Sasaki and Matsui, 2008) . The general lack of repression by DNA methylation at this stage might lead to increased non-specific transcription, including low-level expression of somatic genes that would be expected to abate as the germ cells continue their specific differentiation program (including the activation of germ cellspecific genes). Figures 2c and d show hypermethylated NSCLC genes mapped onto a DT of testis development 11.5dpc to birth at 18.5dpc (GSE6881) and a DT of ovary development from whole ovary at gd 11, 12, 14, 16, 18 and pnd2 (GSE5334), respectively. Interestingly, we find that if our hypermethylated NSCLC genes are mapped onto DTs constructed from gonad development, they preferentially locate at the early end of the DTs in a reversal of the pattern that we observed for lung and ESC development. This observation confirms that the overlap between 'late developmental/differentiation-associated genes' and hypermethylated NSCLC genes holds specifically in the context of somatic differentiation and cannot be observed with respect to every developmental time course.
We next wanted to determine whether the congruence of somatic differentiation-associated and hypermethylated genes only applied to the select subpopulation of genes that were consistently hypermethylated in most patients, or whether our results could be reproduced for every sample. We therefore repeated the analysis for each patient independently, using all the genes that were hypermethylated in a given tumor, with no requirement for consistency across patients. Each sample contained between 120 and 630 genes identified as hypermethylated using a stringent threshold of differential methylation. Figure 3a shows the five sets of hypermethylated genes mapped separately onto the four DTs. The results are in agreement for all five tumors and recapitulate the significant overlap between late developmental and hypermethylated genes, even though the specific genes in each sample by in large do not overlap (Figure 3b ). Thus, despite containing different genes, each hypermethylated set exhibits a bias toward late development in lung and ESC, and toward early development in the gonads. We conclude that even though different genes may be affected by hypermethylation in different NSCLC tumors, they all belong to the same differentiation-associated transcription program.
GO analysis
Next, we used the GO to investigate the biological functions of the hypermethylated NSCLC genes. Table 1 shows the top ten GO biological processes that are overrepresented in the genes hypermethylated in at least four of five samples (see Supplementary Table 3 for a list of all enriched GO categories). In general, biological processes associated with aberrantly methylated genes include many differentiation-specific and late developmental processes important for the formation of structured tissue, which is in line with their location on the late fraction of the DT. The associated cellular components and molecular functions are predominately related to nuclear, regulatory functions, consistent with potential transcription factor roles of these genes. Transcription factor activity, in particular, is significantly enriched. In sum, the GO terms enriched in the hypermethylated NSCLC genes suggest their involvement in morphogenetic processes and late stage differentiation.
Hypermethylated genes in NSCLC cell lines are also differentiation associated We attempted to corroborate our results in primary lung tumors with an analysis of lung cancer cell lines and an alternate method of identifying aberrantly methylated genes-expression analysis of cell lines before and after treatment with a DNA methyltransferase inhibitor. Expression data from seven NSCLC cell lines (GSE5816: NCI-H460, H1299, H157, H2347, H1819, H1993 and A549) were acquired before and after treatment with 5-aza-2 0 -deoxycytidine (5aza-dC) (Shames et al., 2006) . 5aza-dC is widely used to reactivate the expression of genes silenced by methylation (Heller et al., 2010) . It has also been shown to induce cellular differentiation (Taylor and Jones, 1979; Momparler et al., 1985) . Genes that were significantly upregulated in at least four cell lines after treatment were considered to be hypermethylated and were mapped onto the four DTs (Figure 4 ). Once again, we observed a significant bias toward the late fraction of the DTs in lung and ESC, confirming that our initial results are reproducible in a different experimental setting.
Tumor suppressor genes vs differentiation-associated genes It is a prevalent notion that tumor suppressor genes are hypermethylated during tumorigenesis (Esteller, 2002) . Numerous studies have investigated the methylation of specific tumor suppressors in tumorigenesis, but in most studies, only single genes or small numbers of genes were analyzed (Heller et al., 2010) . We wanted to test whether tumor suppressor genes as a group were indeed overrepresented in the genes that we found to be hypermethylated in lung cancer. To this end, we obtained a comprehensive list of known tumor suppressors (n ¼ 436) from the Memorial Sloan-Kettering Cancer Center's Cancer Genes database (http://cbio.mskcc.org/ CancerGenes). We find that the set of hypermethylated NSCLC genes (in four out of five samples) is not significantly enriched for known tumor suppressors (P ¼ 0.06 in a hypergeometric test). We therefore speculate that large-scale methylation patterns in cancer could be more accurately summarized as 'silencing of differentiation-associated genes' rather than 'silencing of Figure 2 Genes hypermethylated in primary lung tumors mapped onto four DTs. Mouse homologs of genes hypermethylated in at least four of five NSCLC samples (n ¼ 102) are mapped onto the DTs of (a) lung, (b) ESC, (c) testis and (d) ovary. The primary lung cancer vs normal lung dual-channel Agilent CpG-island array data were obtained from the public domain (Agilent Technologies, Wilmington, DE, USA). These were already background-corrected, LOWESS normalized, and the resulting dataset of log2-transformed corrected ratios was used in analysis. We compared the distribution of log2 (tumor/normal) values for each primary tumor sample and verified that all were approximately normal with a slight bias toward methylation. To identify the hypermethylated gene sets for each primary tumor sample, we used the method used by Rauch et al. (2008) . A CpG island was considered hypermethylated if it contained at least two adjacent probes (allowing a one-probe gap) exhibiting a fold change of X2 in the tumor sample vs the matched normal tissue. Genes with hypermethylated CpG islands were then matched to their murine homologs. To match genes across developmental (expression) and cancer (methylation) platforms, we used the homologene database (http:// www.ncbi.nlm.nih.gov/homologene) to define orthologs between human and mouse. Q-values were determined using the Broad Institute's GSEA Gseapreranked tool. A list of hypermethylated genes contained within the late region of each DT is included in Supplementary Table 2. Histograms summarize the distribution of hypermethylated cancer genes on each DT. The height of each histogram bar represents the number of genes located in a given segment of the DT.
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In summary, this study shows that the hypermethylation of CpG islands in NSCLC preferentially targets genes that are expressed in late stages of somatic development, and therefore likely involved in establishment and maintenance of differentiation. We corroborate this result in human lung cancer cell lines and present an analysis of the biological processes that characterizes these genes. Based on these insights, we suspect that DNA methylation mechanistically contributes to the establishment of an early developmental, undifferentiated phenotype in cancer. It has been widely observed that DNA methyltransferase inhibitors induce differentiation (Xu et al., 2002; Yoon et al., 2006; Banerjee and Bacanamwo, 2010) . The hypermethylation of differentiation-associated genes in lung cancer could also provide an explanation for the observed induction of differentiation in cells treated with DNA methyltransferase inhibitors. Overrepresented (P-value o0.001) GO annotations for the hypermethylated genes in at least four of five NSCLC samples are displayed in this study according to category: (a) biological processes, (b) cellular components and (c) the molecular functions. Overrepresentation calculated using the R package Gostats (Falcon and Gentleman, 2007) . For Table 1 , we selected the 10 biological processes with the most significant odds ratio and a category size between 100 and 1000. Figure 4 Genes hypermethylated in human NSCLC cell lines mapped onto DTs. Mouse homologs of genes upregulated at least 1.5 standard deviations (distribution of all fold changes) from the mean after treatment with 5-aza-2 0 -deoxycytidine (n ¼ 132) mapped onto (a) lung, (b) ESC, (c) testis and (d) ovary DTs. Expression data from cell lines before and after treatment with demethylating agent, 5-aza-2 0 -deoxycytidine, were acquired from the public domain. The DTs include only those genes present on all platforms in the analysis (14 658 genes). Seven NSCLC cell lines were treated with both 100 and 1000 nM doses of demethylating agent. Hypermethylated genes were selected by the following criteria: genes upregulated by at least 1.5 standard deviations in at least four of the cancer cell lines after a low dosage treatment with 100 nM demethylating agent. See Supplementary Table 1b for list of gene sets.
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